Phase 1 study for people with Myeloma

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 13 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Genentech, Inc.
Registry number NCT05927571
Started 10 August 2023 Today 16 October 2026 Estimated completion 31 July 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Royal Prince Alfred Hospital Camperdown NSW Recruiting
Calvary Mater Newcastle Waratah NSW Recruiting
Royal Adelaide Hospital;Haematology Clinical Trials Unit Adelaide SA Recruiting
St. Vincent's Hospital Melbourne Melbourne VIC Recruiting
The Alfred Hospital Prahan VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 13 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 120

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

* Diagnosis of R/R MM per IMWG criteria

* For female participants of childbearing potential: agreement to remain abstinent or use contraception

* For male participants: agreement to remain abstinent or use a condom

Exclusion Criteria:

* Prior treatment with cevostamab or another agent targeting fragment crystallizable receptor-like 5 (FcRH5)

* Prior treatment with elranatamab

* Prior allogeneic stem cell transplantation (SCT)

* Absolute plasma cell count exceeding 500 per milliliter (mL) or 5% of the peripheral blood white cells

* Diagnosis of Waldenström macroglobulinemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome

* Participants with known history of amyloidosis

* History of autoimmune disease

* History of confirmed progressive multifocal leukoencephalopathy

* Peripheral motor polyneuropathy of prespecified grade

* Known or suspected chronic cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) infection

* Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)

* Acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

* Human immunodeficiency virus (HIV) seropositivity

* History of central nervous system (CNS) myeloma disease

* Significant cardiovascular disease

Dates on the record

Started 10 August 2023
Estimated completion 31 July 2027
Registry last updated 6 October 2026
Checked by Voxsanity 13 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 6 October 2026.
  • This page last checked by Voxsanity: 13 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.